CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 195 enrolled
Drug / intervention
Fluzone® +1 morebiological
Likely dose
Fluzone® 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01262846
NCT01262846Phase 4Completed
CompareCT.gov

Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals

University of Pennsylvania·interventional·Posted Dec 17, 2010·Updated Apr 13, 2017

In Brief

A Phase 4 clinical trial evaluating Fluzone® for HIV Infection. Completed, enrolled 195 participants across 1 site.

Detailed Summary

The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals. Our hypothesis is that Fluzone® HD will be safe and more immunogenic than the currently used vaccine

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2010
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.5 years ago

Interventions

Fluzone®biological

Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.

Fluzone®biological

Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.